Self-screen B.V.
Netherlands Last updated 8 Jun 2026
- Devices
- 4
- Registries
- EUDAMED
- FDA recalls
- 0
Catalogue
QIAscreen HPV PCR test Ref 617005
QIAsure Methylation Test Ref 616014
PreCursor-M+ Ref QHR15100
HPV-Risk assay Ref QHR13172
About
Self-screen's main focus is on cervical cancer screening and prevention. The company has two clinically validated assays on the market. We strive towards all-molecular screening to ensure objectivity, reproducibility and high-throughput possibilities.
What Self-screen B.V. makes
Self-screen B.V. develops an HPV-Risk assay designed for cervical cancer screening, enabling molecular-based risk assessment of human papillomavirus infections.
The HPV-Risk assay is classified under In Vitro Diagnostic (IVD) General and is registered in the EU’s eudamed database. The company is based in the Netherlands.
Frequently asked questions
How many devices does Self-screen B.V. have in the registry?
The registry currently lists 4 devices for Self-screen B.V.. Devices recorded under merged duplicate company entries are counted once.
Which registries list Self-screen B.V.'s devices?
Among its 4 most recently registered devices, Self-screen B.V. has devices listed in EUDAMED (4 devices).
What risk classes do Self-screen B.V.'s devices fall under?
Among its 4 most recently registered devices, the classes recorded for Self-screen B.V.'s devices are IVD general. Each device page shows its own class and authorisation.
What are the newest devices from Self-screen B.V. in the registry?
The most recently registered devices listed for Self-screen B.V. include QIAscreen HPV PCR test, QIAsure Methylation Test, PreCursor-M+ and HPV-Risk assay.
Information
- Address
- 125, Plesmanlaan, Amsterdam, Netherlands
- Website
- www.self-screen.nl
- [email protected]
- Phone
- +31-850805929
- PRRC contact
- Albertus Hesselink
- EUDAMED SRN
- NL-MF-000040204